DE69623559D1 - Verwendung einer amphipatischen, kationischen verbindung als transfektionmittel,als impfstoffadjuvans oder als medikament - Google Patents

Verwendung einer amphipatischen, kationischen verbindung als transfektionmittel,als impfstoffadjuvans oder als medikament

Info

Publication number
DE69623559D1
DE69623559D1 DE69623559T DE69623559T DE69623559D1 DE 69623559 D1 DE69623559 D1 DE 69623559D1 DE 69623559 T DE69623559 T DE 69623559T DE 69623559 T DE69623559 T DE 69623559T DE 69623559 D1 DE69623559 D1 DE 69623559D1
Authority
DE
Germany
Prior art keywords
opt
unsatd
substd
esp
carbocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69623559T
Other languages
English (en)
Other versions
DE69623559T2 (de
Inventor
Jean Haensler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Original Assignee
Aventis Pasteur SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur SA filed Critical Aventis Pasteur SA
Application granted granted Critical
Publication of DE69623559D1 publication Critical patent/DE69623559D1/de
Publication of DE69623559T2 publication Critical patent/DE69623559T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/812—Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DE69623559T 1995-04-11 1996-04-11 Verwendung einer amphipatischen, kationischen verbindung als transfektionmittel,als impfstoffadjuvans oder als medikament Expired - Fee Related DE69623559T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9504615A FR2732895B1 (fr) 1995-04-11 1995-04-11 Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
PCT/FR1996/000547 WO1996032102A1 (fr) 1995-04-11 1996-04-11 Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament

Publications (2)

Publication Number Publication Date
DE69623559D1 true DE69623559D1 (de) 2002-10-17
DE69623559T2 DE69623559T2 (de) 2003-08-07

Family

ID=9478207

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69623559T Expired - Fee Related DE69623559T2 (de) 1995-04-11 1996-04-11 Verwendung einer amphipatischen, kationischen verbindung als transfektionmittel,als impfstoffadjuvans oder als medikament

Country Status (12)

Country Link
US (1) US6124270A (de)
EP (2) EP1245249A3 (de)
JP (1) JPH10501822A (de)
AT (1) ATE223716T1 (de)
AU (1) AU704369C (de)
CA (1) CA2192597A1 (de)
DE (1) DE69623559T2 (de)
DK (1) DK0769942T3 (de)
ES (1) ES2181885T3 (de)
FR (1) FR2732895B1 (de)
PT (1) PT769942E (de)
WO (1) WO1996032102A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2726764B1 (fr) * 1994-11-14 1997-01-31 Pasteur Merieux Serums Vacc Adjuvant pour composition vaccinale
US6331524B1 (en) 1994-12-09 2001-12-18 Genzyme Corporation Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
US6383814B1 (en) 1994-12-09 2002-05-07 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5939401A (en) * 1994-12-09 1999-08-17 Genzyme Corporation Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
US5948767A (en) * 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
AUPN741696A0 (en) * 1996-01-05 1996-01-25 Commonwealth Scientific And Industrial Research Organisation Delivery of nucleic acids ii
CA2286177C (en) 1997-04-07 2011-06-21 Daiichi Pharmaceutical Co., Ltd. Composition for gene transfer into cells
FR2763958A1 (fr) 1997-05-29 1998-12-04 Transgene Sa Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
US6372720B1 (en) 1998-02-05 2002-04-16 Kenneth J. Longmuir Liposome fusion and delivery vehicle
FR2781160B1 (fr) * 1998-07-03 2000-08-18 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique pour adjuver un vaccin sous-unitaire
FR2814958B1 (fr) * 2000-10-06 2003-03-07 Aventis Pasteur Composition vaccinale
JP2005517394A (ja) * 2001-12-12 2005-06-16 エフ エイチ フォールディング アンド カンパニー リミテッド ウイルス保存のための組成物
US20060211004A1 (en) 2005-02-15 2006-09-21 Ilsley Diane D Methods and compositions for determining non-specific cytotoxicity of a transfection agent
EP1938843A1 (de) * 2006-12-19 2008-07-02 Novosom AG Lipide und Lipidanordnungen mit transfektionsverstärkenden Elementen
US8877206B2 (en) * 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
WO2009039628A1 (en) 2007-09-27 2009-04-02 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
WO2009129227A1 (en) 2008-04-17 2009-10-22 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
CA2723918C (en) * 2008-06-05 2018-01-09 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
SG11201401177WA (en) 2011-10-06 2014-04-28 Immunovaccine Technologies Inc Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
TWI672149B (zh) 2012-09-21 2019-09-21 美商Ｐｄｓ生技公司 改良之疫苗組成物及使用方法
GB201315321D0 (en) 2013-08-28 2013-10-09 Koninklijke Nederlandse Akademie Van Wetenschappen Transduction Buffer
US11298326B2 (en) * 2015-03-24 2022-04-12 Kyowa Kirin Co., Ltd. Nucleic acid-containing lipid nanoparticles
WO2017083820A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
EP3778572A4 (de) * 2018-03-27 2021-12-22 NOF Corporation Neues kationisches lipid mit verbesserter intrazellulärer dynamik
EP3646854B1 (de) * 2018-10-30 2022-08-03 PolyPlus Transfection Zusammensetzungen zur transfektion von mrna in eine zelle und deren anwendungen
EP4035686A4 (de) * 2019-09-26 2023-11-01 NOF Corporation Lyophilisierte lipidnanoteilchenzusammensetzung
WO2024018762A1 (ja) * 2022-07-19 2024-01-25 国立大学法人北海道大学 ｐＨ感受性カチオン性脂質及び脂質ナノ粒子

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3906092A (en) * 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
EP0152379A3 (de) * 1984-02-15 1986-10-29 Ciba-Geigy Ag Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend unilamellare Liposomen
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
NZ253943A (en) * 1992-06-18 1997-01-29 Genpharm Int Transfering polynucleotides into eukaryotic cells using co-lipofection complexes of a cationic lipid and the polynucleotide
AUPM747694A0 (en) * 1994-08-16 1994-09-08 Commonwealth Scientific And Industrial Research Organisation Delivery of nucleic acids and peptides
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine

Also Published As

Publication number Publication date
AU704369B2 (en) 1999-04-22
ES2181885T3 (es) 2003-03-01
EP1245249A2 (de) 2002-10-02
ATE223716T1 (de) 2002-09-15
FR2732895A1 (fr) 1996-10-18
FR2732895B1 (fr) 1997-05-16
WO1996032102A1 (fr) 1996-10-17
US6124270A (en) 2000-09-26
CA2192597A1 (fr) 1996-10-17
EP0769942A1 (de) 1997-05-02
EP1245249A3 (de) 2002-12-11
JPH10501822A (ja) 1998-02-17
DE69623559T2 (de) 2003-08-07
DK0769942T3 (da) 2003-01-06
AU5651796A (en) 1996-10-30
EP0769942B1 (de) 2002-09-11
PT769942E (pt) 2003-01-31
AU704369C (en) 2004-03-11

Similar Documents

Publication Publication Date Title
DE69623559D1 (de) Verwendung einer amphipatischen, kationischen verbindung als transfektionmittel,als impfstoffadjuvans oder als medikament
MY102866A (en) Amide derivatives.
RU93056837A (ru) Гексагидронафталиновые сложноэфирные производные, способы их получения и фармацевтическая композиция
ES8406080A1 (es) Un procedimiento para la preparacion de nuevos derivados de fosfolipidos.
IE872588L (en) Compounds
JPS5632474A (en) Piperazine derivative and its preparation
ES8400079A1 (es) Procedimiento para la preparacion de derivados de ciclohexe-no
ATE27813T1 (de) N-substituierte 1-(4'-alkylsulfonylphenyl)-2amino-1,3-propanediol-derivate.
EP0186426A3 (en) Tetrazolyl compounds and their pharmaceutical use
ATE63541T1 (de) N-phenylethylaminoalkyl-benzamide als antiarrhythmische mittel.
PT88095A (pt) Processo para a preparacao de novos compostos com enxofre e de composicoes farmaceuticas que os contem
DE3466981D1 (de) 1-(4'-alkylthiophenyl)-2-amino-1,3-propanediol n-substituted derivatives
ES2027492A6 (es) Procedimiento de preparacion de nuevos derivados dihidropirimidotiazinos y de sus sales de adicion acidas farmaceuticamente aceptables.
DK364386A (da) 1-alkyl-ergolinyl-thiourinstofderivater og fremgangsmaade til fremstilling deraf samt deres anvendelse
GB996490A (en) Dibenzazepine derivatives
KR950032151A (ko) 점착성 수용체 길항제

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8339 Ceased/non-payment of the annual fee